empagliflozin vs ranolazine

According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.

Side-by-side comparison of empagliflozin and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

moderate Known Drug Interaction

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .

Drug Class
empagliflozin SGLT2 Inhibitor
ranolazine Late Sodium Current Inhibitor (Antianginal)
Type
empagliflozin Prescription
ranolazine Prescription
Summary
empagliflozin

No summary available.

ranolazine

Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.

What It Treats
empagliflozin

Information not available.

ranolazine

Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.

How It Works
empagliflozin

Information not available.

ranolazine

Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.

Common Side Effects
empagliflozin
  • Urinary tract infection
  • Yeast infection (in women)
  • Diarrhea
  • Nausea
  • Vomiting
ranolazine
  • Dizziness
  • Headache
  • Constipation
  • Nausea
FAERS Reports
empagliflozin
  • Diabetic Ketoacidosis 3,773
  • Nausea 3,212
  • Blood Glucose Increased 3,043
  • Diarrhoea 2,806
  • Weight Decreased 2,749
ranolazine
  • Death 816
  • Myocardial Infarction 640
  • Chest Pain 605
  • Angina Pectoris 594
  • Stent Placement 582
Serious Warnings
empagliflozin

No specific warnings noted.

ranolazine

Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.

Pregnancy
empagliflozin

No pregnancy information available.

ranolazine

It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.

Also Compare, Nearby Drugs

How to Read This empagliflozin vs ranolazine Comparison

empagliflozin is classified in the SGLT2 Inhibitor drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin has 15,583 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to ranolazine interferes with how the kidneys clear metformin from your system. this can lead to higher levels of metformin in your blood and a higher risk of a dangerous acid buildup.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for empagliflozin or ranolazine.

Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.